✦ LIBER ✦

470 Final results of a phase II study of combination with nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy in patients with HER2-negative metastatic breast cancer

✍ Scribed by S. Glück; C. Lobo; G. Lopes; A. Castrellon; J. Hurley; I. Reis; S. Richman; O. Silva; J. Slingerland; C. Welsh

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Final results of a phase II study ofnab-

✍ Christopher Lobo; Gilberto Lopes; Odalys Baez; Aurelio Castrellon; Annapoorna Fe 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 268 KB

A Randomized Phase II Study of Paclitaxe

✍ Adam Brufsky; Karen Hoelzer; Thaddeus Beck; Robert Whorf; Mark Keaton; Padma Nad 📂 Article 📅 2011 🏛 CIG Media Group, LP. 🌐 English ⚖ 441 KB

A Phase II Trial of Docetaxel With Bevac

✍ Sara A. Hurvitz; Heather J. Allen; Rebecca L. Moroose; David Chan; Christopher H 📂 Article 📅 2010 🏛 CIG Media Group, LP. 🌐 English ⚖ 598 KB

Phase II Study of Gemcitabine and Bevaci

✍ Rachel Borson; Graydon Harker; James Reeves; Thaddeus Beck; Steven Hager; Willia 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 387 KB

Phase II Trial of Nab-Paclitaxel Compare

✍ William J. Gradishar; Dimitry Krasnojon; Sergey Cheporov; Anatoly N. Makhson; Ge 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 380 KB

First-line therapy with gemcitabine and

✍ Djelila Allouache; Sulochana R Gawande; Michele Tubiana-Hulin; Nicole Tubiana-Ma 📂 Article 📅 2005 🏛 BioMed Central 🌐 English ⚖ 275 KB